The technical problem addressed by the present invention is generally directed to liquid or semi-solid pharmaceutical compositions of apomorphine, and uses thereof in treating neurological diseases or disorders, including Parkinson&rsquo；s disease, or conditions associated therewith. The problem is addressed by providing a liquid or semi-solid pharmaceutical composition comprising apomorphine, an acidic amino acid, and a pharmaceutically acceptable carrier, wherein the molar ratio of apomorphine to the acidic amino acid is about 1:0.5 to 1:2.5.
